Overall, the studies so far suggest that frequency and severity of immune-related adverse events and GVHD are higher in anti-PD-1 treated patients than in anti-CTLA-4 treated patients in the post allo-HCT setting. The gene discussed is PDCD1; the disease is graft versus host disease.